Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 9:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 409 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Buprenorphine (Experimental) Clear all
Completed Not applicable Interventional Results available

MHealth Incentivized Adherence Plus Patient Navigation

NCT06027814
View directory record Official record
Conditions
Opioid Use Disorder, Medication Adherence, Polysubstance Drug Use (Indiscriminate Drug Use), Methamphetamine-dependence
Interventions
Patient Navigation and mHealth (PN+mHealth)
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 11, 2026, 9:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Investigation of the Pharmacokinetic Profile of CBD

NCT05269706
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Cannabidiol 200mg, Epidiolex, Cannabidiol 400mg, Placebo
Drug
Lead sponsor
Yasmin Hurd
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 14, 2025 · Synced Oct 11, 2026, 9:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Project STAMINA (Syringe Service Telemedicine Access for Medication-assisted Intervention Through NAvigation)

NCT04575324
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Telemedicine Linkage Intervention
Behavioral
Lead sponsor
Chestnut Health Systems
Other
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Oct 11, 2026, 9:45 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone

NCT07314346
View directory record Official record
Conditions
Healthy Volunteer Study
Interventions
Buprenorphine/Naloxone + BEM/RZR, Methadone +BEM/RZR
Drug
Lead sponsor
Atea Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Hollywood, Florida • Overland Park, Kansas • Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 11, 2026, 9:45 PM EDT
Recruiting Not applicable Interventional

Electronic Cigarettes as a Harm Reduction Strategy Among People With Opioid Use Disorder on Buprenorphine

NCT07202039
View directory record Official record
Conditions
Tobacco-flavored EC, Sweet-Cooling EC, Sweet Non-cooling EC
Interventions
Brief individual counseling sessions
Behavioral
Lead sponsor
Prisma Health-Upstate
Other
Eligibility
21 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 11, 2026, 9:45 PM EDT
Recruiting Phase 4 Interventional

Acceptability and Feasibility of Extended-Release Subcutaneous Buprenorphine on a Mobile Pharmacy Clinic

NCT07176351
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Buprenorphine
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 11, 2026, 9:45 PM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Buprenorphine Plus Baclofen to Increase Analgesia in Healthy Volunteers

NCT04251819
View directory record Official record
Conditions
Acute Pain, Analgesia
Interventions
Placebos, Baclofen 5 mg, Baclofen 10mg
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 11, 2026, 9:45 PM EDT
Completed Phase 3 Interventional

Extension to Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence

NCT00630201
View directory record Official record
Conditions
Opioid Dependence
Interventions
Probuphine (buprenorphine implant)
Drug
Lead sponsor
Titan Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
15
States / cities
Los Angeles, California • National City, California • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2018 · Synced Oct 11, 2026, 9:45 PM EDT
Completed Phase 3 Interventional Results available

Efficacy Study to Evaluate Buprenorphine HCl Buccal Film in Opioid-Experienced Subjects

NCT01675167
View directory record Official record
Conditions
Low Back Pain
Interventions
Buprenorphine, Placebo
Drug
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years and older
Enrollment
815 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
66
States / cities
Birmingham, Alabama • Haleyville, Alabama • Mobile, Alabama + 57 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Oct 11, 2026, 9:45 PM EDT
Recruiting Phase 2 Interventional

E-Cigarettes for Harm Reduction in Smokers With Opioid Use Disorder

NCT05722561
View directory record Official record
Conditions
Opioid Use Disorder, Cigarette Smoking
Interventions
Telehealth Motivational Counseling, Nicotine Replacement Product, National Institute on Drug Abuse (NIDA) Standardized Research Electronic Cigarette (SREC).
Behavioral · Drug · Device
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years to 75 Years
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 11, 2026, 9:45 PM EDT
Completed Phase 2Phase 3 Interventional

Directly Administered HIV Therapy in Methadone Clinics

NCT00279110
View directory record Official record
Conditions
HIV Infections, Heroin Dependence
Interventions
Directly administered antiretroviral therapy (DAART)
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
5
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Oct 11, 2026, 9:45 PM EDT
Completed Not applicable Interventional Results available

Contingency Management to Enhance Office-Based Buprenorphine Treatment

NCT04024059
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Contingency Management for adherence, Contingency Management for abstinence
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Oct 11, 2026, 9:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Intervention to Expand Opioid Use Disorder Treatment Pharmacotherapy Prescribers

NCT02926482
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Prescriber Recruitment Bundle (PRB)
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
Not listed
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
3
States / cities
Tallahassee, Florida • Columbus, Ohio • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 13, 2024 · Synced Oct 11, 2026, 9:45 PM EDT
Enrolling by invitation Phase 4 Interventional

Houston Emergency Opioid Engagement System

NCT03396276
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Suboxone, Brief counseling in the ED, Referral to outpatient treatment, Follow-up coaching
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 11, 2026, 9:45 PM EDT
Recruiting Phase 2 Interventional

Semaglutide for Helping Opioid Recovery

NCT06639464
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Semaglutide, Placebo
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 26, 2025 · Synced Oct 11, 2026, 9:45 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Dose Conversion From Vicodin® to Buprenorphine Transdermal System (Butrans™) in Subjects With OA Pain

NCT00312572
View directory record Official record
Conditions
Osteoarthritis
Interventions
Buprenorphine transdermal patch
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
40 Years to 85 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2012 · Synced Oct 11, 2026, 9:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Increasing MAT Engagement With Financial Incentives

NCT04585399
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Contingency management
Behavioral
Lead sponsor
Rowan University
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 11, 2026, 9:45 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of Buprenorphine Extended-Release Subcutaneous Injection at Alternative Injection Locations

NCT05704543
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Buprenorphine Extended-Release Injection
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
6
States / cities
San Diego, California • Hollywood, Florida • Miami Lakes, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Oct 11, 2026, 9:45 PM EDT
Completed Not applicable Interventional Results available

Coordinating Opioid Use Treatment Through Medical Management With Infection Treatment (Project COMMIT)

NCT04180020
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
ID/LAB, TAU
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
New Haven, Connecticut • Hershey, Pennsylvania • Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 11, 2026, 9:45 PM EDT
Completed Phase 1Phase 2 Interventional

ALK33BUP-201: Safety and Tolerability Study of ALKS 33-BUP (ALKS 5461) Administration in Subjects With MDD

NCT01381107
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
ALKS 5461, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
2
States / cities
St. Petersburg, Florida • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 23, 2011 · Synced Oct 11, 2026, 9:45 PM EDT
Completed Phase 4 Interventional

Long-acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-involved Adults

NCT04219540
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
XR-B (SUBLOCADETM), XR-NTX
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
675 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
New Haven, Connecticut • Baltimore, Maryland • Hanover, New Hampshire + 3 more
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 11, 2026, 9:45 PM EDT
Completed Phase 2 Interventional

Buprenorphine Maintenance Dose Schedule and Treatment Setting - 1

NCT00000318
View directory record Official record
Conditions
Opioid-Related Disorders, Substance-Related Disorders
Interventions
Buprenorphine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 55 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2007
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 11, 2026, 9:45 PM EDT
Completed Not applicable Interventional Results available

Discontinuation From Chronic Opioid Therapy For Pain Using a Buprenorphine Taper

NCT02737826
View directory record Official record
Conditions
Chronic Pain, Opioid Pain Medication
Interventions
Buprenorphine Initiation - Phase I, Gabapentin + Buprenorphine - Phase II, Placebo + Buprenorphine - Phase II, Buprenorphine taper - Phase II
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Oct 11, 2026, 9:45 PM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Comparison of Three Opioid Detoxification Treatment Regimens

NCT03678792
View directory record Official record
Conditions
Opioid-Related Disorders, Opioid Withdrawal
Interventions
Buprenorphine/naloxone, Morphine, Tramadol
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 5, 2019 · Synced Oct 11, 2026, 9:45 PM EDT